Disease-free survival was greater with letrozole than tamoxifen in postmenopausal women with early breast cancer

July 2006
ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p11
Academic Journal
The article presents information on a study which shows a comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. In the study, researchers find how disease free survival is greater with letrozole than tamoxifen in postmenopausal women with early breast cancer. The study findings suggest that in postmenopausal women with early hormone-receptor-positive breast cancer, adjuvant therapy with letrozole resulted in greater disease-free survival than tamoxifen. Exclusion criteria contain evidence of metastatic disease in the previous five years.


Related Articles

  • Should Tamoxifen Be Used in Breast Cancer Prevention? Kramer, Rita; Brown, Powel // Drug Safety;2004, Vol. 27 Issue 13, p979 

    Breast cancer is the most commonly diagnosed cancer in women. The risk of developing breast cancer can be lowered by maintaining a healthy bodyweight and avoiding long-term use of combined estrogen and progestogen replacement after menopause. However, many women are at an increased risk of...

  • Estrogen plus progestin increased risk for breast cancer in postmenopausal women.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p61 

    In postmenopausal women, estrogen plus progestin hormone therapy (HT) increases cases of total and invasive breast cancer and abnormal mammogram results. Women who have received HT had a greater incidence of total and invasive breast cancer than did women who received placebo. The increase in...

  • Treatment of oestrogen deficiency in women with previous breast cancer. Marsden, Jo // Journal of the British Menopause Society;2000 Supplement, Vol. 6, p18 

    The article discusses the management of estrogen deficiency in women with previous breast cancer. The widespread use of tamoxifen, chemotherapy and gonadotropin-releasing hormone agonists suppress the effects of endogenous estrogens and may induce a premature menopause. Low-dose progestogens and...

  • Breast cancer risk factors in Turkish women - a University Hospital based nested case control study. Ozmen, Vahit; Ozcinar, Beyza; Karanlik, Hasan; Cabioglu, Neslihan; Tukenmez, Mustafa; Disci, Rian; Ozmen, Tolga; Igci, Abdullah; Muslumanoglu, Mahmut; Kecer, Mustafa; Soran, Atilla // World Journal of Surgical Oncology;2009, Vol. 7, p1 

    Background: Breast cancer has been increased in developing countries, but there are limited data for breast cancer risk factors in these countries. To clarify the risk for breast cancer among the Turkish women, an university hospital based nested case-control study was conducted. Methods:...

  • Tamoxifen with or without Breast Irradiation in Women 50 Years of Age or Older with Early Breast Cancer. Fyles, Anthony W.; McCready, David R.; Manchul, Lee A.; Trudeau, Maureen E.; Merante, Patricia; Pintilie, Melania; Weir, Lorna M.; Olivotto, Ivo A. // New England Journal of Medicine;9/2/2004, Vol. 351 Issue 10, p963 

    Background: We determined the effect of breast irradiation plus tamoxifen on disease-free survival and local relapse in women 50 years of age or older who had T1 or T2 node-negative breast cancer. Methods: Between December 1992 and June 2000, 769 women with early breast cancer (tumor diameter, 5...

  • Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. Bertelsen, Lisbeth; Bernstein, Leslie; Olsen, Jørgen H.; Meilemkjær, Lene; Haile, Robert W.; Lynch, Charles F.; Malone, Kathleen E.; Anton-Culver, Hoda; Christensen, Jane; Langholz, Bryan; Thomas, Duncan C.; Begg, Colin B.; Capanu, Marinela; Ejlertsen, Bent; Stovall, Marilyn; Boice Jr., John D.; Shore, Roy E. // JNCI: Journal of the National Cancer Institute;1/2/2008, Vol. 100 Issue 1, p32 

    Background: Results from randomized trials indicate that treatment with tamoxifen or chemotherapy for primary breast cancer reduces the risk for contralateral breast cancer. However, less is known about how long the risk is reduced and the impact of factors such as age and menopausal status....

  • Tamoxifen and BRCA mutations.  // Caribbean Health;Apr2001, Vol. 4 Issue 2, p32 

    The article reports on the study which shows that tamoxifen reduces the risk of breast cancer in high-risk women and of contralateral breast cancer in women having breast cancer. The study suggested that it is effective in preventing contralateral breast cancer in women with breast cancer and a...

  • Use of paroxetine during tamoxifen therapy for breast cancer was associated with increased breast-cancer and all-cause mortality. Hillner, Bruce E. // ACP Journal Club;6/15/2010, Vol. 152 Issue 6, p12 

    The article comments on a study related to the association between use of paroxetine during tamoxifen therapy for breast cancer and increased risk of breast-cancer and all-cause mortality in patients in Ontario, Canada. The findings of the study indicated that women who received paroxetine had...

  • More on HRT and breast cancer risk. Kirchner, Jeffrey; D'Epiro, Peter; Russell, John J. // Patient Care;Nov2003, Vol. 37 Issue 11, p70 

    Discusses research being done on breast cancer and hormone-replacement therapy in women studies. Reference to a study by V. Beral et al., published in a 2003 issue of "The Lancet"; Impact of the therapy on the development of breast cancer; Effect of hormone-replacement therapy on patients who...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics